|
| 37208237 | Management of Lymph Node-positive Penile Cancer: A Systematic Review. | Eur Urol | 2024 |
| 37757472 | Cancer and the risk of perioperative arterial ischaemic events. | Eur Heart J Qual Care Clin Outcomes | 2024 |
| 37922438 | Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of <sup>225</sup>Ac-J591. | J Clin Oncol | 2024 |
| 36939530 | Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer. | Clin Cancer Res | 2023 |
| 38071107 | Systematic Review and Meta-analysis of Minimally Invasive Procedures for Surgical Inguinal Nodal Staging in Penile Carcinoma. | Eur Urol Focus | 2023 |
| 37608258 | Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4Â weeks versus 2Â weeks (SHORTER). | BMC Cancer | 2023 |
| 37221397 | Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [<sup>18</sup>F]DCFPyL PET/CT in prostate cancer men. | Sci Rep | 2023 |
| 37290800 | SNMMI Consensus Statement on Patient Selection and Appropriate Use of <sup>177</sup>Lu-PSMA-617 Radionuclide Therapy. | J Nucl Med | 2023 |
| 37424145 | Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy. | Prostate | 2023 |
| 37419845 | Antibody-drug conjugates for urothelial carcinoma. | Urol Oncol | 2023 |
| 37101768 | Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. | Eur Urol Open Sci | 2023 |
| 37269841 | Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2023 |
| 37032186 | Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022. | Eur Urol | 2023 |
| 37163648 | α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States. | J Nucl Med Technol | 2023 |
| 36960580 | Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature. | Prostate | 2023 |
| 36906413 | European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. | Eur Urol | 2023 |
| 36571987 | Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial. | Transl Oncol | 2023 |
| 36635088 | Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. | J Nucl Med | 2023 |
| 34363009 | PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 35652416 | Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes. | J Thromb Haemost | 2022 |
| 35840724 | Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. | Prostate Cancer Prostatic Dis | 2022 |
| 35540709 | What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes. | Eur Urol Open Sci | 2022 |
| 35388003 | Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. | Nat Commun | 2022 |
| 35657341 | The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. | JNCI Cancer Spectr | 2022 |
| 36575731 | Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan. | Onco Targets Ther | 2022 |
| 35046520 | Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. | Br J Cancer | 2022 |
| 34985786 | Pilot study of the diagnostic utility of <sup>89</sup> Zr-df-IAB2M and <sup>68</sup> Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer. | Prostate | 2022 |
| 35039606 | Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. | Prostate Cancer Prostatic Dis | 2022 |
| 35032754 | Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis. | J Stroke Cerebrovasc Dis | 2022 |
| 35231161 | The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. | Mol Oncol | 2022 |
| 33090917 | Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. | J Urol | 2021 |
| 33853746 | A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges. | Urol Oncol | 2021 |
| 33680970 | Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. | Front Oncol | 2021 |
| 33596187 | PSMA-targeted therapy in prostate cancer. | Clin Adv Hematol Oncol | 2021 |
| 33648895 | Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond. | Eur Urol Focus | 2021 |
| 33894633 | Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. | Eur J Cancer | 2021 |
| 33612825 | Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. | Prostate Cancer Prostatic Dis | 2021 |
| 33778927 | Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. | Curr Oncol Rep | 2021 |
| 33929895 | TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. | J Clin Oncol | 2021 |
| 33495926 | A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. | Eur J Nucl Med Mol Imaging | 2021 |
| 34529003 | Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy. | JAMA Oncol | 2021 |
| 34491818 | Reply to T. Powles et al. | J Clin Oncol | 2021 |
| 34725947 | Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration. | Cancer Med | 2021 |
| 34541577 | Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma. | Skin Health Dis | 2021 |
| 34796255 | A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. | Am J Clin Exp Urol | 2021 |
| 34161051 | Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. | N Engl J Med | 2021 |
| 34219002 | A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer. | Urol Oncol | 2021 |
| 34099734 | Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. | Nat Commun | 2021 |
| 33989025 | Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). | J Clin Oncol | 2021 |
| 34091024 | Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolization, a Pilot Study. | J Vasc Interv Radiol | 2021 |